“The TRANBERG portfolio complements our current offering in laser technology for cancer treatment in the urology field in an excellent way,” says Eric Girard, CEO of MTEC.
According to WHO Approximately 1 men are diagnosed with prostate cancer each year globally, of which approximately 400 are in the EU and 000 in France. The current treatment options for localized (non-spread) prostate cancer are surgery or radiotherapy, which are associated with significant risks and side effects such as incontinence and erectile dysfunction.
Clinical Laserthermia Systems (CLS) offers a minimally invasive treatment option through focal laser ablation with the company's TRANBERG Thermal Therapy System. Focal therapy treats only the affected area, reducing the risk of affecting surrounding healthy tissue. The system also has temperature control, allowing healthcare professionals to continuously monitor the temperature to optimize treatment and minimize the risk of side effects.
MTEC has a long history in the laser field
Now CLS chooses to launch the TRANBERG system in France together with MTEC, which specializes in the distribution of medical and surgical lasers. Established in 1994, MTEC has since provided solutions to healthcare professionals and institutions throughout France. The collaboration with CLS strengthens the company's offering in urology:
“We can now offer a new platform of laser technology, designed to treat localized prostate cancer with great precision, to both our large existing customer base and to new physicians,” says MTEC’s CEO. Eric Girard.
Participation in national conference
The next step in the market launch is participation at the national scientific BPH/prostate meeting in Bordeaux between May 23-24. MTEC will exhibit the TRANBERG system, with support from CLS.
– This meeting will be attended by important opinion leaders in the prostate cancer field and the meeting provides an excellent platform for the broader market introduction in France, CLS writes in its press release.
“With our presence at a local conference, we demonstrate our commitment, not only to our new commercial partner, but also to some of the most influential specialists in the French market,” adds Perjan Pleunis, VP Sales Europe, CLS.
Initial commercial phase and clinical study
Perjan Pleunis believes that the collaboration with MTEC is a small but important first commercial milestone in the French market. Since December 2023, the CLS laser ablation system has also been used in the French national study IRMPROFT, which evaluates MRI along with biopsy to detect residual prostate cancer after focal therapy.
Now CLS looks forward to taking the first commercial step in France:
– I look forward to the collaboration with MTEC, and I am convinced that their expertise and network will contribute to a successful launch of the CLS TRANBERG system in France, says Perjan Pleunis.